VICTORIA GUNTER: Open Payments
NPI 1215711452 · PENSACOLA, FL. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$3,907 in 202 payments from 16 companies in 2025. Trend: 2023 $260 · 2024 $1,308 · 2025 $3,907
Food & beverage: $3,907
| Company | Payments | Amount |
|---|---|---|
| Neurocrine BioSciences, Inc. | 23 | $752 |
| Alkermes, Inc. | 21 | $527 |
| Teva Pharmaceuticals USA, Inc. | 26 | $420 |
| Otsuka America Pharmaceutical, Inc. | 23 | $391 |
| E.R. Squibb & Sons, L.L.C. | 23 | $379 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 19 | $325 |
| ABBVIE INC. | 25 | $318 |
| Vanda Pharmaceuticals Inc. | 11 | $219 |
| Lundbeck LLC | 10 | $174 |
| Axsome Therapeutics, Inc. | 7 | $132 |
Products named: INGREZZA, REXULTI, ARISTADA, COBENFY, CAPLYTA, VRAYLAR, AUSTEDO XR, FANAPT.
Industry payments across FL — which companies pay providers there.
